mefloquine has been researched along with Astrocytoma, Grade IV in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dos Santos, JL; Fernandes, BC; Fernandes, GFDS; Valente, V | 1 |
| Huang, B; Wan, B; Wu, Z; Zhang, X | 1 |
| Aldape, KD; Alfred Yung, WK; Conrad, CA; de Groot, JF; Gilbert, MR; Groves, MD; Hess, KR; Loghin, ME; Mammoser, AG; Maraka, S; Melguizo-Gavilanes, I; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Sulman, EP; Tremont-Lukats, IW | 1 |
| Nevin, RL | 1 |
| Groves, MD; Maraka, S; Penas-Prado, M | 1 |
1 review(s) available for mefloquine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Recent advances in the discovery of small molecules targeting glioblastoma.
Topics: Animals; Central Nervous System Neoplasms; Drug Discovery; Glioblastoma; Humans; Neoplastic Stem Cells | 2019 |
1 trial(s) available for mefloquine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Mefloquine; Memantine; Metformin; Middle Aged; Progression-Free Survival; Radiotherapy, Adjuvant; Research Design; Temozolomide; Treatment Outcome; Young Adult | 2019 |
3 other study(ies) available for mefloquine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Mefloquine as a dual inhibitor of glioblastoma angiogenesis and glioblastoma via disrupting lysosomal function.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Male; Mefloquine; Mice, SCID; Neovascularization, Pathologic | 2021 |
Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma.
Topics: Glioblastoma; Humans; Mefloquine; Memantine; Metformin; Temozolomide | 2019 |
Reply to Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma.
Topics: Glioblastoma; Humans; Mefloquine; Memantine; Metformin; Temozolomide | 2019 |